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Background: Even though increasing evidences on miRNA involvement in human pathological responses, the
distinct roles and related mechanisms of miRNAs in the pathology of osteoarthritis (OA) are not yet fully under-
stood.
Method: RNA levels or protein levels of Apoptotic genes, HDACs, MMP-13, and miRNAs in human chondrocytes
isolated from normal biopsy sample and OA cartilages were analyzed by real-time PCR or western blotting. Ex-
ogenous modulation of miR-222 level was performed using delivery of its speciﬁc precursor or speciﬁc inhibitor
and target validation assay was applied to identify its potent target. In vivo study using DMM mice model was
performed and assessed the degree of cartilage degradation.
Results: According to miRNA proﬁling, miR-222 was signiﬁcantly down-regulated in OA chondrocytes. Over-
expression of miR-222 signiﬁcantly suppressed apoptotic death by down-regulating HDAC-4 and MMP-13
level. Moreover, 3′-UTR reporter assays showed that HDAC-4 is a direct target of miR-222. The treatment of
chondrocytes with the HDAC inhibitor, trichostatin A (TSA), suppressed MMP-13 protein level and apoptosis,
whereas the over-expression of HDAC-4 displayed opposite effects. The introduction of miR-222 into the carti-
lage of medial meniscus destabilized mice signiﬁcantly reduced cartilage destruction and MMP-13 level.
Conclusion: Taken together, our data suggest that miR-222 may be involved in cartilage destruction by targeting
HDAC-4 and regulating MMP-13 level.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteoarthritis (OA), which is a chronic degenerative joint disorder
that causes joint pain and dysfunction, is characterized by progressive
structural changes in articular cartilage, persistent loss of tissue cellular-
ity, anddegeneration of the extracellularmatrix (ECM) [1]. Chondrocytes
are the only resident cells found in cartilage and are responsible for both
synthesis and turnover of the abundant ECM [2]. Therefore, the mainte-
nance of healthy chondrocytes appears to be important for maintaining
cartilage integrity. Another signiﬁcant feature of OA is excessive produc-
tion of inﬂammatory mediators [3]. Among them, the pro-inﬂammatory
cytokine, interleukin-1β (IL-1β), plays a crucial role by inducing a cas-
cade of inﬂammatory and catabolic events. In particular, IL-1β alters
chondrocyte anabolism by enhancing matrix metalloproteinase (MMP)
production which suppresses cartilage matrix formation. Among thel Sciences, College of Natural
, Korea. Fax: +82 63 850 6197.
. This is an open access article underMMPs, the expression of MMP-13 is signiﬁcantly higher in chondrocytes
from late-stage OA cartilage compared with early OA or normal knee
cartilage [4]. In addition, transgenic mice over-expressing MMP-13 in
their articular chondrocytes develop a joint degradation similar to that
seen in human OA [5]. Little and colleagues [6] showed that MMP-13-
deﬁcient mice are resistance to osteoarthritic cartilage erosion, which
caused by proteolysis of the principal cartilage matrix such as aggrecan
and cartilage collagens suggesting cartilage structural damage in OA is
highly dependent onMMP-13 activity.Moreover, they have demonstrat-
ed that a signiﬁcant inhibition of cartilage structural damage in DMM-
induced MMP-13–knockout is associated with a change in chondrocyte
hypertrophy, apoptosis, or osteophyte development not reduction in
aggrecanolysis. However, the mechanisms underlying the pathological
characteristics of OA are still not fully understood.
Two families of histone deacetylases (HDACs) have been identiﬁed:
the classical HDAC family and theNAD+-dependent, the so-called SIR2
family (sometimes called class III HDACs). The classical HDACs can be
grouped into three classes (I, II, and IV) based on phylogeny [7]. The
class I HDACs (HDAC-1, -2, -3, and -8) are related to yeast RPD3, and
the class II HDACs (HDAC-4, -5, -6, -7, -9, and -10) are closely relatedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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shows broad-spectrum activity against class I and class II HDACs. Re-
cently, HDACs have emerged as therapeutic targets in cancer and
inﬂammatory diseases, including rheumatoid arthritis (RA) and OA
[10–13]. However, it is still unclear exactly how HDACs are involved in
cartilage degradation.
MicroRNAs (miRNAs, miRs) have emerged as ﬁne-tuning regulators
for diverse biological processes [14,15]. During their biogenesis, the
miRNA genes are transcribed into primary miRNAs (pri-miR), which
are processed by Drosha and Dicer to generate miRNA duplexes
consisting of a mature and a passenger miR strand [16]. Recent studies
have shown thatmiRNAs play crucial roles in immune cell development
and immune system function [17,18] and regulate various aspect of cell
physiology, including developmental timing, cell differentiation, apo-
ptosis, and anti-viral defense [18–20]. Given the crucial role of miRNAs
in human physiology, the abnormal expression of speciﬁc miRNAs may
lead to the development of diverse diseases, such as cancer, cardiovas-
cular disorders, mental disorders, musculoskeletal disorders, and lung
diseases [21–25]. Recently, intensive research has focused on delineat-
ing the roles of various miRNAs in the development of inﬂammatory
and immune-mediated diseases. Here, we report that miR-222 controls
cartilage degradation via HDAC-mediated regulation of MMPs during
OA pathogenesis.
2. Materials and methods
2.1. Cartilage procurement and processing
Cartilagewas obtained from6normal donors (age range 25–49 years)
and 20 OA donors (age range 55–75 years). Tissue collection was
approved by the Human Subjects Committee of Wonkwang University.
Osteoarthritis cartilage was obtained from patients undergoing knee
replacement surgery. Cartilage thickness ranged from 1.5 to 2.8 mm. Car-
tilage surfaces were rinsed with saline, and parallel sections 5 mm apart
were cut vertically from the cartilage surface onto subchondral bone
with a scalpel.
2.2. Primary cultures of human chondrocytes
Small slices of cartilage were sequentially digested with 0.06%
bacterial collagenase (Sigma) then seeded at a density of 1.5 × 104
cells/cm2 in culture medium consisting of DMEM (Gibco-Invitrogen)
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin,
and 100 μg/ml streptomycin (Gibco-Invitrogen). Cells were treated
with 5 ng/ml for IL-1β (R&D systems, Minneapolis, MN), 3 ng/ml for
TGF-βs (R&D systems, Minneapolis, MN), and 300 nM for TSA (Sigma,
St Louis, MO, USA) in this study.
2.3. Western blot analysis
Total proteins (30 μg) were electrophoresed and transferred to
nitrocellulose membranes (Schleicher and Schuell, Keene, Germany).
The membranes were individually probed with antibodies speciﬁc for
Type I, II collagen, PRTG (Calbiochem, La Jolla, CA), (p)AKT, (p)GSK,
(p)JNK, GAPDH (Santa Cruz Biotechnology Inc.), Caspase-3, PARP,
HADC-1, -2, -3, or -4 (Cell Signaling Technology Inc., Danvers, MA,
USA). The blots were developed using a peroxidase-conjugated second-
ary antibody, and the immunoreactive proteins were visualized with an
ECL system (Amersham, UK).
2.4. RNA isolation and quantitative PCR analysis
Total RNA was extracted using the RNeasy Mini Kit (Qiagen). Total
RNA was extracted from cells using TRIzol reagent. Isolated RNA
was treated with DNase followed by reverse transcription of 1 μg RNA
into cDNA using reverse transcriptase, 0.5 μg/μl oligodT primers, and12.5 mM dNTPs (Invitrogen). Quantitative real-time PCR was per-
formed using StepOne plus system (Applied Biosystems, Foster City,
CA). PCR protocol was as follows: 50 °C for 2 min and 95 °C for 10 min
followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. All PCRs
were performed using SYBR green master mix (#436759, Applied
biosystems) and 5 μM of forward and reverse primer in a total reaction
volume of 25 μl. For mRNA, transcripts were quantiﬁed by real-time
quantitative polymerase chain reaction (RT-PCR) and normalized to
the amount of GAPDH mRNA expressed The oligonucleotides used as
primers were as follows: human MMP-2, 5′-acaccaagaacttcgtctg-3′
and 5′-tgcagatc tcaggagtgaca-3′; human MMP-9, 5′-atttctgccaggacc
gcttctact-3′ and 5′-atgtcataggt cacgtagcccact-3′; human MMP-12, 5′-
gaaccaacgcttgccaaatcctga-3′ and 5′-ttcccacggtagt gacagcatcaa-3′;
human MMP-13, 5′-ttgcagagcgctacctgagatcat-3′ and 5′-tttgccagtcac
ctcta agccgaa-3′.
For analyzing the RNA levels of HDACs, the following primers
were used for real-time PCR. HDAC1 (histone deacetylase 1), 5′-gac
acgccaagtgtgtggaa-3′ and 5′-cctcccagcatcagca tagg-3′; HDAC10 (his-
tone deacetylase 10), 5′-caacgccggat atcacattg-3′ and 5′-gctgacgcttcct
gttgga-3′; HDAC11 (histone deacetylase 11), 5′-acaa cccagctgtacc
agcat-3′ and 5′-cgcggcgagta cacgatt-3′; HDAC2 (histone deacetylase
2), 5′-acatgagcaatgcggagaaat-3′ and 5′-tctgccatcttgtgg tacagtga-3′;
HDAC3 (histone deacetylase 3), 5′-ccttttccagccg gttatca-3′ and 5′-
acaatgcacgt gggttggt-3′; HDAC4 (histone deacetylase 4), 5′-tcagat
cgccaacacattcg-3′ and 5′-acgggagcggtt ctgttaga-3′; HDAC5 (histone
deacetylase 5), 5′-ccattggagacgtggagtacct-3′ and 5′-gcggagactag gac
cacatca-3′; HDAC6 (histone deacetylase 6), 5′-tcgctgcgtgtcctttcag-3′
and 5′-gctgtgaaccaaca tcagctctt-3′; HDAC7 (histone deacetylase 7), 5′-
caagag caagcgaagtgctgta-3′ and 5′-ttcagaatca cctccgctagct-3′; HDAC8
(histone deacetylase 8), 5′-tgggaggaggaggctat aacc-3′ and 5′-ccggt
caagtatgtccagcat-3′; HDAC9 (histone deacetylase 9), 5′-cacacacgtg
cgctctctgt-3′ and 5′-cgagac ggtgtttctctaatcca-3′;
For analyzing the RNA levels of genes involved in apoptotic cell
death, the following primers were used for real-time PCR. ABL1 (c-abl
oncogene 1, non-receptor tyrosine kinase), 5′-gaagcccaaaccaaaaatgg-
3′ and 5′-gactgttga ctggcgtgatgtag-3′; APAF1 (apoptotic peptidase acti-
vating factor 1), 5′-tgcgctgctctgccttct-3′ and 5′-gcggagcacaca aatgaaga-
3′; ATP6V1G2 (ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit
G2), 5′-ggaaaacatcctgacttcagtgtct-3′ and 5′-ccagcaagtgacagggtcaa-3′;
BAX (BCL2-associated X protein), 5′-ccaaggtgccggaactga-3′ and 5′-
cccggagg aagtccaatgt-3′; BCL2L11 (BCL2-like 11), 5′-gctttcccatggtcac
aggat-3′ and 5′-ctgca gctggactctgctgta-3′; BIRC2 (baculoviral IAP repeat
containing 2), 5′-cctgtggtggg aagctcagt-3′ and 5′-cctccggtgttctgacatagc-
3′; CASP1 (caspase 1–apoptosis-related cysteine peptidase) ; 5′-
ataccaagaactgcccaagtttg-3′ and 5′-ggcaggcctggatgatga-3′, CASP3 (cas-
pase 3–apoptosis-related cysteine peptidase); 5′-gcctacagcccatttc
tccat-3′ and 5′-gcgccctggcagcat-3′; CASP6 (caspase 6–apoptosis-related
cysteine peptidase), 5′-ggc gtggttactcacacctgta-3′ and 5′-gatcc
gcccaccttgga-3′; CASP7 (caspase 7–apoptosis-related cysteine pepti-
dase), 5′-ccgccgt gggaacgat-3′ and 5′-cctcaaccccctgctcttc-3′; CASP9
(caspase 9–apoptosis-related cysteine peptidase), 5′-agcagtgggctca
ctctgaag-3′ and 5′-aacagcattagcgaccctaagc-3′; CD40 (CD40 molecule,
TNF receptor superfamily member 5), 5′-tggtgagtgactgcacagagttc-3′
and 5′-cgcttt caccgcaagga-3′, CD40LG (CD40 ligand), 5′-ccaggtgcttcggt
gtttgt-3′ and 5′-ccagtgccatggctcactt-3′; CFLAR (CASP8 and FADD-like
apoptosis regulator), 5′-gctggcagctgattagatggt-3′ and 5′-ttt gagtcagt
ggactgggaaa-3′ ; CYLD (cylindromatosis-turban tumor syndrome), 5′-
tgtggaggg cttgcaatgt-3′ and 5′-agc tgagatgtccggatcgt-3′; DFFA (DNA
fragmentation factor, 45 kDa, alpha polypeptide), 5′-ttgacgctccctg
ctcaga-3′ and 5′-tggacggtggcacaactct-3′; FAS (Fas-TNF receptor
superfamily, member 6), 5′-acccgctcagtacggagttg-3′ and 5′-ccagcatgg
ttgttgagcaa-3′; FASLG (Fas ligand-TNF superfamily, member 6), 5′-
tgcctcctctt gagcagtca-3′ and 5′-tcc tgtagaggctgaggtgtca-3′; GADD45A
(growth arrest and DNA-damage-inducible, alpha), 5′-gatgtggc
tctgcagatcca-3′ and 5′-atgtcgttct cgcagcaaaa-3′; NOL3 (nucleolar pro-
tein 3-apoptosis repressor with CARD domain), 5′-gccca ccacgagcatca-
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ated 2), 5′-cccctcccattgcaaagc-3′ and 5′-gtggatgtttggt gacctgaag-3′;
SYCP2 (synaptonemal complex protein 2), 5′-ttagttgatcttctgct ggtca
taca-3′ and 5′-gcgaggtacgaaactttccactac-3′; TNFRSF10A (tumor necro-
sis factor receptor superfamily, member 10a), 5′-gaacacagcatgtcag
tgcaaa-3′ and 5′-ccggcacatctca gcagaat-3′; TNFRSF1A (tumor necrosis
factor receptor superfamily, member 1A), 5′-agcctggagtgcacgaagtt-3′
and 5′-tgagtcctca gtgcccttaaca-3′, TNF (tumor necrosis factor), 5′-
gcaggtctactttgggatcattg-3′ and 5′-gcgtttggg aaggttgga-3′; TP53 (tumor
protein p53), 5′-tgcaataggtgtgcgtcagaa-3′ and 5′-ccccgggacaaagcaaa-
3′; human GAPDH, 5′-gatcatcagcaatg cctcct-3′ and 5′-tgtggtcatgagtcc
ttcca-3′.
2.5. MiRNA and mRNA real-time quantitative RT-PCR
MiRNA and mRNA expression were independently quantiﬁed using
the TaqMan MicroRNA and TaqMan gene expression assays (Applied
Biosystems), respectively, according to the manufacturer's protocols.
MiRNA expressionwas normalized to RNU43 small nuclear RNA endog-
enous controls.
2.6. Reporter vectors and DNA constructs
The 3′-UTR of humanHDAC-4was PCR ampliﬁed using the following
primers: 5′-TGGGAGCTCCTGGCTCTATT-3′ (bp no. 1616 ~ 1635), 5′-
GCTGAGGCTGACTTTGCACT-3′ (bp no. 3088 ~ 3107). It was then cloned
downstream of the CMV-driven ﬁreﬂy luciferase cassette in the pMIR-
REPORT vector (Ambion). For miRNA target validation, chondroblasts
were electroporated with 200 ng of a ﬁreﬂy luciferase reporter con-
struct and 50 pmol of pre-miR-222 or pre-miR-negative (Ambion).
The Renilla luciferase vector was used to normalize electroporation efﬁ-
ciency. At 24 h after electroporation, both ﬁreﬂy and Renilla luciferase
activity were assayed (Promega). Normalized relative light units repre-
sent ﬁreﬂy luciferase activity or Renillar luciferase activity.
2.7. Production of lentiviral particles
The hsa-miR-222 and negative control lentiviruses were transfected
with 3rd generation packaging mix from Applied Biological Materials
Inc. (ABM) into human 293FT cells using Lentifectin (ABM) in Opti-
MEM I medium (Invitrogen, CA) and cultured overnight. The superna-
tant was collected and lentiviral particles were concentrated using
Lenti-X Concentrator (Clontech, CA).
2.8. Arthritic cartilage, experimental OA, and histology of OA cartilage
Human OA cartilage was sourced from individuals undergoing
arthroplasty for OA of the knee joint. The Wonkwang University
Hospital Institutional ReviewBoard approved the use of thesematerials,
and all individuals provided written informed consent before the oper-
ative procedure. Human OA cartilage samples were frozen, sectioned at
a thickness of 10 μm, ﬁxed in paraformaldehyde, and stained with
safranin O.
Experimental OA was induced by destabilization of the medial
meniscus (DMM) surgery 8-week-old male mice. The care and use of
experimental animals were approved by our Institutional Animal Care
and Use Committee. Sham-operated animals injected with empty lenti-
viruses (mock transduction)were used as controls for DMM.Micewere
killed 8 weeks after DMM surgery or 2 weeks after intra-articular injec-
tion (1 × 109 plaque-forming units (PFU)) of miR-222-expressing lenti-
viruses for histologic and biochemical analyses. Cartilage destruction in
mice was examined using safranin O staining. Brieﬂy, knee joints were
ﬁxed in 4% paraformaldehyde, decalciﬁed in 0.5 M EDTA (pH 7.4) for
14 days at 4 °C, and embedded in parafﬁn. The parafﬁn blocks were sec-
tioned at 6 μm thickness. The sections were deparafﬁnized in xylene,
hydrated with graded ethanol, and stained with safranin O. For MMP-13 staining, sections were incubated with anti-MMP-13 antibody
(1:200 dilutions) overnight at 4 °C, followed by incubation with
TRITC-conjugated secondary antibody at room temperature for 1 hour.
For propidium iodide staining, sections were incubated with 50 μg/ml
propidium iodide and 50 μg/ml RNase A in PBS.2.9. Cell apoptosis assay
MuseTM apoptosis kit (Millipore, Billerica, MA) were used to detect
apoptotic cell death.2.10. RNA Extraction from FFPE (formalin-ﬁxed parafﬁn-embedded) tissue
of mouse cartilages
RNA was extracted from the parafﬁn samples using the MasterPure
kit (Epicentre Biotechnologies, Madison, WI). Brieﬂy, FFPE tissue was
resuspended in MasterPure tissue and cell lysis solution with a ﬁnal
concentration of 0.15 mg/ml proteinase K and incubated at 65 °C for
30 min. MasterPure MPC™ protein precipitation reagent was added
and nucleic acids were precipitated by adding isopropanol and pelleted
by centrifugation at 10,000×g for 10 min at 4 °C. The remaining pellet
was washed twice with 75% ethanol and allowed to dry before adding
30 μl TE buffer with 40 units of RNase inhibitor.2.11. Statistical analysis
Statistically signiﬁcant differences between 2 groups were deter-
mined with t tests. Results are presented as mean± standard deviation
(SD). P values of less than 0.05 were considered statistically signiﬁcant.3. Results
3.1. Apoptosis and HDAC expression are elevated in OA cartilage
Osteoarthritic (OA) cartilage samples (n= 10) were obtained from
patients who underwent joint surgery (mean age, 64.6 years). The car-
tilage was divided into non-OA and OA areas and stained with safranin
O (Fig. 1A, right panel). Proteolytic degradation of cartilage is a hallmark
of osteoarthritis (OA), and activated chondrocytes are known to pro-
ducematrix-degrading enzymes, such asMMP-13 (also known as colla-
genase 3) in OA joints [26,27]. Consistent with these previous reports,
the expression of MMP-13 (Fig. 1A middle panel) was increased in the
OA cartilage compared to the non-OA cartilage. Apoptotic cell death
was also signiﬁcantly increased in the OA areas (Fig. 1A, left panel).
Moreover, we found that various apoptotic genes, including ABL1,
ATP6V1GNOL3, CASP-1, -3 and -7, CD40, CYLD, and FAS, were highly
induced in OA chondrocytes (Fig. 1B).
HDACs balance the activities of histone acetyltransferases (HATs)
and epigenetically regulate gene transcription, thereby controlling
the acetylation status of histone proteins and non-histone sub-
strates. Recent studies have demonstrated that HDAC inhibitors
have therapeutic effects in cancer and inﬂammatory diseases
[10–13,28–32]. To further characterize the molecules involved in
OA pathogenesis, we examined the RNA levels of the genes encoding
HDAC-1 through HDAC-11 in OA chondrocytes isolated from carti-
lage of OA patients compared to normal chondrocytes isolated from
biopsy sample of normal patients. Our results revealed that the
RNA levels of all of these genes were highly up-regulated in OA
chondrocytes, particularly those encoding HDAC-4 and -9 (Fig. 1C,
left panel). In addition, we observed the signiﬁcant up-regulation
of HDAC-4 expression in 10 different OA chondrocytes compared to
normal chondrocytes (Fig. 1C, right panel).
AB
C
Fig. 1. Apoptosis and histon deacetylation were involved in the pathogenesis of OA. (A) OA cartilage that was divided into 2 classes depending on the progression of OA pathology (Non-
OA: healthy zone; OA: severe OA zone) and stained with safranin O (left panel). Chondrocytes were isolated from biopsy sample of normal cartilage (normal) and OA cartilage (Non-OA
andOA) and the RNA level ofMMP-13 (middle panel) and apoptotic cell death (right panel)were analyzed usingMuseTM apoptosis kit. H&E stainingwas inserted. (B) Changes in the RNA
level of genes involved in apoptosis were analyzed by RT-PCR. (C) Changes in the RNA level of HDAC-1 to -11 genes were analyzed by RT-PCR (left panel) and changes in the RNA level of
HDAC-4 using OA chondrocytes isolated from 10 different OA patients (right panel). GAPDH was used as control. The mean is plotted, and the error bars represent 95% CI (lower/upper
limit). *Statistically different from control cells (p b 0.05).
82 J. Song et al. / BBA Clinical 3 (2015) 79–893.2. MiR-222 contributes to OA pathogenesis by modulating the induction
of MMPs
Recent studies have uncovered the important and crucial roles for a
family of small regulatory RNA molecules known as microRNAs (miR;
miRNAs) in regulating diverse aspect of diseases by acting as a majorgene switch [33]. To identify miRNAs that could be involved in mod-
ulating HDAC gene expression in OA chondrocytes, we ﬁrst exam-
ined their expression levels in normal, non-OA, and OA cartilage to
verify the OA-related miRNAs selected from previous publications.
As shown in Fig. 2A, miR-9, -22, -130a, -140-3p, -143, -122, and
-222 were down-regulated in OA chondrocytes and degenerated
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Fig. 2.miR-222 is involved in degeneration of human articular chondrocytes. (A) Chondrocytes were isolated from biopsy sample of normal cartilage (normal) and OA cartilage (OA),
cultured with or without 5 ng/ml IL-1β. OA. Expression levels of miRs were analyzed. (B) Chondrocytes were isolated from biopsy sample of normal cartilage (normal) and OA cartilage
(Non-OA and OA) and expression level ofmiR-222 (left panel)was analyzed by real-time PCR. Expression level ofmiR-222was analyzed using OA chondrocytes isolated from 10 different
OA patients (right panel). The mean is plotted and the error bars represent 95% CI (lower/upper limit). *Statistically different from control cells (p b 0.05).
83J. Song et al. / BBA Clinical 3 (2015) 79–89chondrocytes by IL-1β compared to normal chondrocytes, whereas
miR-124 was up-regulated in OA chondrocytes and degenerated
chondrocytes by IL-1β. Among them, miR-222 was observed to be sup-
pressed by 4-fold in OA chondrocytes and 3-fold in IL-1β-treated
chondrocytes (Fig. 2A). We analyzed the expression level of miR-222
in non-OA chondrocyte and OA chondrocytes compared to normal
chondrocytes. Suppressed level of miR-222 was observed in both non-
OA chondrocytes and OA chondrocytes and its level was gradually
decreased as pathogenesis progressed (Fig. 2B, left panel). Moreover,
we observed the signiﬁcant down-regulation of miR-222 expression
in 10 different OA chondrocytes (Fig. 2B, right panel).
To verify the involvement of miR-222 in the degeneration of human
articular chondrocytes, biopsy samples of normal cartilage from seven
adult donors without history of joint disease (mean age 40.4 years)
were used for the isolation of primary articular chondrocytes and treat-
edwith IL-1β or TGF-β1, -2, or -3.With exposure of IL-1β to cells, we ob-
served an increase in cells having a degenerative morphology (Fig. 3A,
upper panel). The expression level of miR-222 was signiﬁcantly de-
creased by IL-1β and signiﬁcantly increased by TGF-β1, 2, 3 (Fig. 3A,
lower left panel). Moreover, the RNA level of MMP-13 was signiﬁcantly
increased by IL-1β, whereas the MMP-13 was signiﬁcantly suppressedby TGF-β1, -2, or -3 (Fig. 3A, lower right panel). The RNA levels of the
apoptotic genes including ABL-1, CASPs, CD40, and FAS were signiﬁ-
cantly up-regulated with IL-1β-treatment (Fig. 3B).
To further investigation to verify the involvement of miR-222 in the
degeneration of human articular chondrocyte, normal chondrocytes
were treated with miR-222 precursor (miR-222) or miR-222 inhibitor
(anti-miR-222) in the presence of IL-1β or TGF-β3, and the RNA level
ofMMP-13was analyzed. The introduction of anti-miR-222 dramatical-
ly increased the RNA level of MMP-13 in IL-1β-treated and TGF-β3-
treated chondrocyteswhereas the introduction ofmiR-222wasdramat-
ically inhibited IL-1β-induced degenerative phenotype and RNA level of
MMP-13 (Fig. 3C). In addition, the introduction of miR-222 recovered
protein level of type II collagen (Fig. 3D) and rescued cell viability
(Fig. 3E), which were suppressed by IL-1β treatment.
3.3. MiR-222 targets HDAC-4 that involved in regulation of MMP-13 and
chondrocytes apoptosis
To validate the involvement of miR-222 in up-regulating HDACs in
OA chondrocytes, normal chondrocytes were electroporated with
miR-222 or anti-miR-222 in the presence of TGF-β3 or IL-1β. The
84 J. Song et al. / BBA Clinical 3 (2015) 79–89efﬁciency of miR-222 or anti-miR-222 was conﬁrmed with RT-PCR
(Fig. 4A, left panel). The administration of miR-222 signiﬁcantly sup-
pressed the protein level of HDAC-4 in IL-1β-treated chondrocytes,
whereas anti-miR-222 increased HDAC-4 expression (Fig. 4A, right
panel). To validate the interaction between miR-222 and HDAC-4, we
cloned the entire 3′-UTR of HDAC-4 into a luciferase reporter vector,
electroporated the vector into normal chondrocytes alongwith the pre-
cursor of miR-222 or a cognate non-targeting negative control, and
assayed cell lysates for luciferase expression. We found that cells
transfectedwith the HDAC-4 3′-UTR-driven vector plusmiR-222 exhib-
ited signiﬁcantly less luciferase activity compared to cells that received
the reporter plus the non-targeting negative control (Fig. 4B).
To examine the role of histone acetylation in OA pathogenesis, we
treated OA chondrocytes with Trichostatin A (TSA), an HDAC inhibitorA
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Fig. 3B, were down-regulated by TSA treatment (Fig. 4E).
3.4. Modulation of miR-222 regulates OA pathogenesis in vivo
To examine the role of miR-222 in OA and to determine whether
its modulation could control the pathogenesis of OA in vivo, we
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Fig. 3 (continued).
85J. Song et al. / BBA Clinical 3 (2015) 79–89DMMmouse knee joints. As shown in Fig. 5, the cartilage destruction
caused by DMM surgery was signiﬁcantly reduced by the over-
expression of miR-222, whereas it was intensiﬁed by suppression of
miR-222. Consistent with this, enhanced RNA and protein levels of
MMP-13 were decreased by the over-expression of miR-222 and in-
creased by suppression of miR-222 in DMM-induced mice. The RNA
level of HDAC-4 was also decreased by the over-expression of miR-222
in DMM-induced mice. According to nuclei staining, the introduction
of miR-222 recovered cell number which was signiﬁcantly decreased
by DMM surgery. Semi-quantitative scoring of the cartilage destruction
seen in safranin-O-stained photomicrographs of the medial femoral
condyle (MFC) andmedial tibial plateau (MTP) indicated thatDMMsur-
gery scored 1.2 for theMFC view and 1.5 for the MTP view. More severe
cartilage destruction was observed in photomicrographs of DMMmicethat had been infected with lentiviruses encoding the miR-222-speciﬁc
siRNA (miR-222 inhibitor, MFC score of 3.2, MTP score of 3.7).
4. Discussion
The primary pathogenic events in OA include loss and abnormal re-
modeling of the cartilage ECM. The accumulation of degraded fragments
increases MMP-13 synthesis via a positive feedback loop that involves
cell-surface integrins, resulting in the destruction of knee joints [34].
Consistent with previous ﬁndings [35], we herein conﬁrmed that the
RNA and protein level of MMP-13 were increased in OA cartilage.
Furthermore, increased protein level of MMP-13 in OA chondrocytes
was suppressed by TSA treatment, indicating that TSA may reduce
cartilage degradation by suppressing MMP-13. Several reports have
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Fig. 4.miR-222 targets HDAC-4 and regulatesMMP-13 activation. (A) Chondrocyteswere isolated frombiopsy sample of normal cartilage (control) and culturedwith 3 ng/ml of TGF-β3 in
the presence of miR-222 precursor (pre-miR-222) or miR-222 inhibitor (anti-miR-222). Expression level of miR-222 was analyzed (left panel) and changes in the protein level of HDACs
were analyzed by immunoblotting (right panel). GAPDHwas used as loading control. (B) Luciferase reporter gene assays of cells expressing the construct containing the human HDAC-4
3′-UTR in the absence or presence ofmiR-222. (C) OA chondrocytes isolated formOA cartilagewere treatedwith 300 nMTSA, changes in protein level of activeMMP-13 andHDAC-4were
analyzed by immunoblotting (left panel), and changes in RNA levels of MMP-13 were analyzed by RT-PCR (right panel). GAPDHwas used as loading control. (D) OA chondrocytes were
infectedwith lentiviruses containingHDAC-4. Changes inHDAC-4 andMMP-13were analyzed by immunoblotting. GAPDHwas used as loading control. (E) OA chondrocyteswere treated
with 300 nM TSA changes in the RNA level of genes involved in apoptosis were analyzed by RT-PCR and results were represented as heat-map using Qiagen program. “Red” indicates
high relative expression, and “green” indicates low relative expression. The mean is plotted and the error bars represent 95% CI (lower/upper limit). *Statistically different from control
cells (p b 0.005).
86 J. Song et al. / BBA Clinical 3 (2015) 79–89shown that HDAC inhibitors can repress the expression of MMPs in
human chondrocytes. For example, Young et al. [36] showed that
TSA repressed MMP-3 expression in human chondrocytes. Nasu
et al. [31] noted that it repressed MMP-13 in the same cells; and
multiple reports have shown that TSA decreases MMP-2 expression
in different cell types [37,38]. These results and our present ﬁndings
indicate that HDAC inhibitors can suppress the expression of MMPs
depending on cell types, environmental conditions, and other
factors.
The HDACs participate in chromatin remodeling by deacetylating
lysine residues and play pivotal roles in the epigenetic regulation of
gene expression [39]. Aberrant HDAC activity has been documented in
several types of disease, and HDACs have emerged as an attractivetherapeutic target. However, the histone modiﬁcation of chondrocytes
has not been extensively studied in OA. Most of the existing studies
have examined the ability of HDAC to block cartilage degradation
by repressing the induction of cytokines and MMPs [36,40]. Intra-
articular injection of the HDAC inhibitor, TSA, was shown to protect
against cartilage degradation during the development of OA in an ex-
perimental model [41], suggesting that HDAC activity is crucial for the
catabolic activity of chondrocytes. HDAC inhibition is also known to
modulate the RNA levels of anabolic cartilage genes, such as COL2A1,
COL9A1, COMP, and ACAN [42,43]. In OA, HDAC-7 is expressed in OA
cartilage, where it controls MMP-13 expression [44]. Here, we further
found that HDAC-4 is highly up-regulated in OA chondrocytes com-
pared to normal chondrocytes.
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Fig. 5.miR-222 involved in the pathogenesis of OA in DMMmice. Mouse cartilages with OA induced by destabilization of the medial meniscus (DMM) were stained with safranin O and
MMP-13 (upper panel). Cartilage destruction was scored according to the guidelines of the OARSI histopathology initiative, the average scores of theMFC andMTPwere plotted, and the
RNA levels of HDAC-4 andMMP-13were analyzedusing RNAs isolated fromparafﬁn section ofmice cartilages (n=4) (lower panel). Sham-operated (Sham) cartilagewas used as control.
The mean is plotted, and the error bars represent 95% CI (lower/upper limit). *Statistically different from control cells (p b 0.005).
87J. Song et al. / BBA Clinical 3 (2015) 79–89Recent studies have shown that miRNAs may exert their activity by
interfering with the epigenetic machinery, such as by modulating the
expression of enzymes that regulate DNA methylation or histone
modiﬁcation [45,46]. For example, miRNA-449a regulates histoneacetylation status in prostate cancer cells by targeting HDAC-1 [47],
and miRNA-9 and -206 contribute to regulating histone acetylation
and HDAC-4 activity in Waldenström macroglobulinemia cells [48].
However, we do not yet know which miR genes are altered by HDACs
88 J. Song et al. / BBA Clinical 3 (2015) 79–89during OA pathogenesis, and only a few miRNAs are known to be in-
volved in the modulation of HDACs in OA. The present study provides
crucial information on the regulation of HDAC-4 during the pathogenesis
of OA. We focused on upstream regulators of enhanced acetylation and
found several miRNAs that were deregulated in OA chondrocytes versus
normal chondrocytes.
Previous studies on miRNAs in cartilage have been largely restricted
to a few speciﬁc miRNAs. Iliopoulos and colleagues [49] showedmiRNA
proﬁling in OA cartilage compared to normal cartilage and found 16
osteoarthritic miRNAs includingmiR-22, miR-140, andmiR-483. Unlike
to Iliopoulos experiments, OA chondrocytes were isolated from OA car-
tilages of OA patients who had undergone TKR surgery and cultured
prior to osteoarthritic miRNA proﬁling. Our miRNA proﬁling shared
several miRNAs including miR-140 with Iliopoulos and colleagues. A
cartilage-restricted miRNA, miR-140, was shown to target HDAC-4
[50,51], a repressor of Runx249 and Smad3 [52,53] in mice, and
ADAMTS5 [54,55] and IGFBP5 [56] in humans. Null mice of miR-140
showed an early-onset OA-like disease [54]. MiR-365 and miR-27
have also been shown to be involved in OA pathogenesis by targeting
HDAC-4 and MMP-13, respectively [57].
There are major issues with the therapeutic use of HDAC inhibitors,
such as their lack of speciﬁcity, their lack of isoform selectivity, and their
lack of known targets [58]. Thus, this study has important therapeutic
implications and provides a “ﬁne tuning” means of speciﬁcally regulat-
ing HDAC-4 for the control of OA. In summary, we herein report that
miR-222 is one of the miRNAs responsible for cartilage degradation in
human OA chondrocytes, where it targets HDAC-4 and thereby alters
MMP-13 activity. This suggests that miR-222 may serve as a potential
HDAC-4 inhibitor for the therapeutic control of OA.
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